©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
The N-terminal Cytoplasmic Tail of the Aspartate Receptor Is Not Essential in Signal Transduction of Bacterial Chemotaxis (*)

(Received for publication, July 11, 1995)

Xiaomin Chen Daniel E. Koshland , Jr. (§)

From the Department of Molecular and Cell Biology, University of California, Berkeley, California 94720

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

To determine the role in transmembrane signaling of the N-terminal peptide of the first transmembrane region of the aspartate receptor, it was subjected to extensive mutagenesis. Drastic changes did not alter the chemotactic ability of the receptor to aspartate significantly. Thus the cytoplasmic N terminus of the first transmembrane region does not play an essential role in transmembrane signaling, and the entire signal that is transmitted to the cytoplasmic domain must be sent through the second transmembrane region. This eliminates the models requiring an interaction of this N-terminal peptide with the remaining cytoplasmic portion of the receptor.


INTRODUCTION

Receptor-mediated transmembrane signaling is important in all living organisms from bacteria to human beings. Most receptors function as either homodimers or heterodimers (for recent reviews see Refs. 1 and 2). The dimerization process is sometimes induced by ligand binding and sometimes totally independent of it. The human growth hormone receptors belong to the first category(3) . Others, such as human insulin receptor (4) and the bacterial chemotactic receptors(5) , do not change their oligomeric states upon ligand binding. These receptor families share similar transmembrane topology (one or two single transmembrane segments connecting an extracellular ligand binding domain and an intracellular signal domain in each subunit). They are believed to transmit signals by a common mechanism, because chimeric receptors containing the ligand binding domain of one receptor and the signaling portion of another are still capable of transmembrane signaling(6, 7) . Due to the detailed understanding of the biochemical pathways of the bacterial chemotaxis system and the relative ease in manipulating bacterial proteins, the aspartate receptor provides us with an excellent system to study the general principles underlining the signal transduction mechanism.

Each aspartate receptor subunit has a periplasmic ligand binding domain, two transmembrane segments (transmembrane (TM) (^1)1 and TM 2), and one cytoplasmic domain. The native receptor has two subunits that do not associate or dissociate during signaling(5) . The aspartate binding sites, as seen in the x-ray crystal structure, lie at the interface between the two subunits(8) . Cross-linking experiments with introduced cysteine residues at various locations of the receptor showed that the signal is a conformational change of the receptor(9) . It can be transmitted through one subunit of the functional dimer(10) .

When the alanine residue (at position 19) in the middle of TM 1 was replaced by a lysine residue (A19K), the mutant receptor was nonfunctional, even though the binding affinity for aspartate remained similar to that of the wild type(11) . The pseudorevertants of this A19K mutant were largely found within a 40-residue region (residues 264-303) of the cytoplasmic domain. Thus there might be some interactions between the cytoplasmic domain and the TM 1, probably through the cytoplasmic extension of TM 1, a six-residue tail at the N-terminal end of the receptor sequence, and this interaction might be important for transmembrane signaling.

Short or long C-terminal tails exist in a number of receptors, but their role is still uncertain at the moment (for recent reviews see (12, 13, 14) ). The N-terminal tail of the aspartate receptor is highly conserved in the chemotactic receptor family (Table 1). In order to clarify its role in the signal transduction process, extensive mutations have been introduced into that region, and the cells with the modified receptors have been examined.




MATERIALS AND METHODS

Bacterial Strains and Plasmids

Escherichia coli strain CJ236 (dut ung) was from BioRAD. XL1-Blue and XL2-Blue were from Stratagene. RP3808 (Delta(cheA-cheZ)2209 tsr-1) and RP8611 (Deltatsr7028 Delta(tar-tap)5201 zbd::Tn5 Delta(trg)100) were gifts from Dr. J. S. Parkinson at the University of Utah. HCB721 (15) was from Dr. H. C. Berg at Harvard University. Plasmids pEMBL18+ and pBTac2 were from Boehringer Mannheim.

Chemicals and Media

N-Ethylmaleimide, n-octyl-beta-D-glucopyranoside (OG), S-adenosyl-L-methionine, -aminooctyl-agarose gel, thiamine, and the amino acids L-histidine, L-methionine, L-leucine, and L-threonine were from Sigma. L-Aspartic acid, Zwittergent 3-12, and isopropylthio-beta-D-galactoside were from Calbiochem. S-adenosyl-L-[^3H]methionine, L-[2,3]-[^3H]aspartic acid, and S-protein A were purchased from Amersham Corp. Dithiothreitol was from Boehringer Mannheim. Mutagenic oligonucleotides were either from Operon Technologies (Alameda, CA) or from the DNA Synthesis Facility of the University of California at Berkeley. The Centriprep-30 ultrafiltration tubes were from Amicon. The T4 Mutagene kit, the protein assay kit, and the Affi-Protein A MAPS II kit were from Bio-Rad. The fmol DNA sequencing system was from Promega.

The minimal medium contains Vogel-Bonner citrate salt(16) , 1% glycerol, 100 µg/ml ampicillin, and 500 mg/liter of each of the following: L-histidine, L-methionine, L-leucine, L-threonine, and thiamine. The Luria broth contains 1% tryptone, 0.5% yeast extract, and 1% NaCl. The minimal plates have 0.3% agar in minimal medium. The aspartate plates are the same as the minimal ones except that aspartate was added to 100 µM. The tryptone plates have 1.3% tryptone, 0.6% NaCl, 0.3% agar, and 100 µg/ml ampicillin.

Mutant Construction

Site-directed mutagenesis was carried out according to Kunkel(17) . For technical reasons, one set of the oligonucleotides contain an EcoRI restriction site right upstream of the start codon of the tar(s) gene, in addition to the desired mutations. A second set has only the individual mutations in the oligonucleotides. The pXC09 plasmid contains the wild type tarS gene, as an insert in the pEMBL18 vector. Single-stranded pXC09 DNA template was prepared from CJ236. The mutagenesis reactions were performed using a Mutagene kit according to the user's manual. The mutagenic products were used to transform XL1-Blue or XL2-Blue cells. Plasmids were prepared by standard alkaline lysis method, and the mutants were confirmed by double-stranded DNA sequencing. The class A plasmids are pEMBL18-based. The receptor gene in this class was expressed under the control of its natural promoter. Class B plasmids were constructed by ligating the small EcoRI-HindIII restriction fragments of class A plasmids into the pBTac2 vector cleaved with the same restriction enzymes. The receptor genes in this class were expressed under the control of the tac promoter.

Swarm Assay

The plasmids listed in Table 2were used to transform E. coli strain RP8611, which has none of the four chemotactic receptor genes. Cells were grown from single colonies in a 1-ml Luria broth with 100 µg/ml ampicillin (LB+Amp) at 30 °C overnight. Then they were inoculated onto the center of the minimal, aspartate, or tryptone plates, using a sealed Pasteur pipet tip. The plates were incubated at 30 °C overnight with the soft surface facing up. Swarm diameters were measured five times over an 8-10-h period starting approximately 14 h after inoculation. Swarm rates were extrapolated from the diameter versus time plots as the slopes of the linear fits of the points.



Overexpression of the Aspartate Receptor

Overexpression of the aspartate receptor was carried out by transforming RP3808 or HCB721 with various plasmids. Cells containing the class B plasmids were grown in 50 ml of LB+Amp over night at 37 °C. Then overnight culture was transferred into 1 liter of minimal medium and grown at 30 °C. Cells were harvested when A reached 1.0-1.6. Cells containing the class A plasmids were grown in 50 ml of LB+Amp at 30 °C overnight. 23 ml of the overnight culture were transferred into 1 liter fresh LB+Amp and allowed to continue growing at 30 °C for 8-10 h before harvesting. Cells containing the class C plasmids were grown in 10 ml of LB+Amp overnight at 37 °C. The overnight culture was transferred into 1 liter of LB+Amp and grown at 30 °C. Isopropylthio-beta-D-galactoside was added to 0.5 mM when A reached 0.5-1.0. Cells were harvested 3 h later. The harvested cells were frozen immediately in liquid nitrogen and stored at -80 °C until the membrane preparation.

Membrane Preparation

All steps were carried out at 4 °C. Frozen cells were thawed on ice and low salt buffer (100 mM NaPi, pH 7.0, 10% glycerol, 5 mM EDTA, and 1 mM PMSF) was added to 6-12 ml/liter culture. Cells were broken by sonication. The lysed cells were centrifuged at 5,000 times g for 15 min until there was no visible pellet formed. The supernatant portion was then spun at 38, 000 rpm (Ti 45 rotor) for 25 min. The pellet was washed twice in high salt buffer (20 mM NaPi, pH 7.0, 2 M KCl, 10% glycerol, 5 mM EDTA, and 1 mM PMSF) and once in final buffer (50 mM Tris-Cl, pH 7.5, 10% glycerol, 5 mM EDTA, 1 mM PMSF, and 5 mM 1,10-phenanthroline). Finally the membrane was resuspended in 1 ml/liter culture of final buffer, mixed well, frozen in liquid nitrogen, and stored at -80 °C until use. For the membrane preparations of the cysteine mutants, 5 mM dithiothreitol was added in all buffers. The membrane prepared from RP3808 with pEMBL18 was called null membrane, because it had no tar gene present. The amounts of the receptor in the membrane samples were quantified by quantitative immunoblotting analyses, using purified receptor as standard and S-labeled protein A. The anti-Tar antibody was purified from anti-serum (alpha-Tar(e) #9206 prepared by H.-P. Biemann) using the Affi-Protein A MAPS II kit.

Receptor Purification

All steps were carried out at 4 °C. The membrane sample was thawed on ice. The detergent OG was added to 1.4% (w/v), and the sample was left on ice for 10 min. The solubilized membrane proteins were separated from membrane vesicles by ultracentrifugation at 95,000 rpm for 10 min (TLA 100.3 rotor). Ammonium sulfate was added to 20% (w/v) to the supernatant fraction. The precipitated protein was pelleted by centrifugation at 5,000 rpm for 10 min (HS-4 rotor) and was resuspended in Zwittergent buffer (20 mM Tris-Cl, pH 7.5, 10% glycerol, 1 mM EDTA, 0.1 mM PMSF, and 0.4% Zwittergent 3-12). Then the proteins were loaded onto an -aminooctyl-agarose column pre-equilibrated with Zwittergent buffer. After washing the column with three volumes of the Zwittergent buffer, the proteins were eluted with a linear gradient of 0-750 mM NaCl in 20-bed volume OG buffer (same as the Zwittergent buffer except that it contained 1.2% OG instead of 0.4% Zwittergent 3-12). The receptor peak was identified by SDS-polyacrylamide gel electrophoresis, and the fractions were pooled and dialyzed against OG buffer overnight. The receptor sample was concentrated to 0.3-0.6 mg/ml of total protein, using Centriprep-30 ultrafiltration tubes. An equal volume of 100% glycerol (w/v) was added to the protein solution, and it was stored at -20 °C. Protein concentration was determined by Bradford protein assay (18) using the Bio-Rad protein assay kit.

Aspartate Binding Assay

The binding assays were done as published ( (19) and (20) and references therein) with minor modifications as follows. Membrane samples were mixed with various amounts of aspartate in a final volume of 200 µl. After incubating on ice for more than 10 min, 90 µl of the mixture were transferred into a TLA100 ultracentrifuge tube containing 1 µl of either water or 100 mM cold aspartate. Membrane was pelleted by a 10-min centrifugation at 95,000 rpm. Triplicates of 20 µl of the supernatant fraction were added to a scintillation vial containing 150 µl of water. Then 2 ml of scintillation mixture was added, and radioactivity was counted. Binding data were analyzed (using the Kaleidagraph 3.0 program, Abelbeck Software) by fitting the curve of bound aspartate concentration versus free aspartate concentration to the Hill equation,

where B and F are the concentrations of bound and free aspartate, respectively, B(max) is the maximal bound aspartate concentration, K(d) is the dissociation constant, and n(H) is the Hill coefficient.

Methylation Assays

Methylation assays were performed either in the membrane vesicle system or in the reconstituted system. The methyltransferase was prepared according to Shapiro and Koshland(21) . For membrane methylation assays, receptor-containing membranes were mixed with an equal volume of the methylation mixture (100 µCi of S-adenosyl-L-[^3H]methionine, 150 mM NaPi, pH 7.0, 30 mM EDTA, 1 mM PMSF, and 4-10 µl of methyl-transferase/ml of mixture) with or without 2 mM aspartate. At various times, part of the reaction mixture was removed and dotted on a piece of 3 M filter paper, and the paper immediately dropped in 10% trichloroacetic acid with stirring. After the final time point was taken, the filter papers were left in 10% trichloroacetic acid for 10 min and then washed twice with 10% trichloroacetic acid and twice with methanol for 10 min each. Finally the filter papers were air-dried and added to a vial containing 3 ml of scintillation mixture. The radioactivity was counted. The counts/minute values were plotted against time. The methylation rate was reported as the slope of the linear fitting of the time points.

For the methylation of purified receptors in a reconstituted system, partially purified receptor sample was added into the reconstitution buffer (50 mM NaPi, pH 7.0, 40% glycerol, 1/10 volume of null membrane, 0.5% OG, and 1 mM PMSF) and incubated at room temperature for 45 min and then the procedure above was followed.

Cross-linking of the Cysteine-containing Mutant Receptor

The membrane samples were spun down to remove an excess amount of dithiothreitol and resuspended in the final buffer. After pre-incubation at 37 °C for 5 min, the catalyst copper-(phenanthroline)(3)(9) was then added to a final concentration of 1 mM to start the reaction. At various time points, an aliquot of the reaction mixture was removed, added to a tube containing 3 times SDS sample buffer with 10 mM EDTA (to chelate Cu) and 10 mMN-ethylmaleimide (to quench the free thiol groups), and frozen immediately in liquid nitrogen. The samples were then subjected to SDS-polyacrylamide gel electrophoresis, and the regions containing the dimeric and monomeric form of the receptor were excised. The content of radioactive methyl groups in the gel slice was then determined by a previously described methanol diffusion assay(22) .


RESULTS

Several mutants within the N-terminal cytoplasmic tail region of the Salmonella typhimurium aspartate receptor were made (Table 2). Three of them were deletion mutants: Arg^4 deleted (DeltaR4), four residues deleted from Phe^2 to Ile^5 (Delta2-5), and Ile^5 and Arg^6 deleted (Delta5-6). Four of them were point mutations that converted Arg^4 to Gly (R4G), Glu (R4E), Lys (R4K), and Cys (R4C), respectively. The last one (ICys2) was an insertion of a cysteine residue between Met^1 and Phe^2. Two cysteine-containing mutants, R4C and ICys2, allowed us to cross-link the receptor molecules with disulfides.

In order to optimize the overexpression of the aspartate receptor, an EcoRI restriction site was placed immediately upstream of the tar(s) start codon so that the tar(s) gene could be subcloned into another vector that has a strong promoter. It was designed in the same oligonucleotide carrying each of the several N-terminal mutations (class B mutants). This approach also made the screening easier. Unfortunately, this EcoRI site altered the putative ribosome binding site for the receptor synthesis(23) . It indeed lowered the expression level of the receptor (data not shown). These mutants were eventually subcloned into the plasmid pBTac2, and the expression of these class C receptor mutants were much better (data not shown). The oligonucleotides for the rest of the mutants (class A) only contained the desired mutations, and tar(s) gene is under the control of its natural promoter (Table 2).

We performed in vivo swarm assays to test the effects of the mutations on chemotaxis. As shown in Fig. 1, cells harboring each of the mutant receptor genes showed normal responses toward aspartate in the medium compared with those with wild type receptor genes, and the cells containing no receptor gene showed the same swarm rates in the presence and absence of aspartate. Fig. 2shows the swarm rates of the mutants on tryptone plates. The results agree with those in Fig. 1. Thus it seems that a wide variety of mutations at the N-terminal tail region do not impair the chemotactic ability of the cells significantly.


Figure 1: Swarm rates of the N-terminal mutants on minimal and aspartate plates. Swarm assays were performed at 30 °C on the minimal medium plate with or without attractant aspartate. Swarm rates (mm/h) were reported as the slopes of the linear fits of the time-course data points. For each receptor, the column on the left is the swarm rate in the absence of aspartate and the column on the right is that in the presence of aspartate. Top, class A mutants (see ``Results'' for details); middle, class B mutants; bottom, class C mutants. wt, wild type.




Figure 2: Swarm rates of the N-terminal mutants on tryptone plates. Swarm assays were performed at 30 °C on the tryptone plates. Swarm rates (mm/h) were reported as the slopes of the linear fits of the time-course data points. Top, class A mutants (see ``Results'' for details); middle, class B mutants; bottom, class C mutants. wt, wild type.



The exceptions were the R4G mutant of class B ( Fig. 1and Fig. 2) and the R4C mutant of class A ( Fig. 1and Fig. 2). The R4G mutant in class B was very poorly expressed. However, when it was subcloned into pBTac2, the expression level was comparable with other mutants, and it swarmed normally ( Fig. 1and Fig. 2). The R4C mutant showed lower swarm rates than most of the others on both aspartate and tryptone plates, but its rates were still higher than those of the negative controls. For each swarm assay, we did immunoblotting analysis to monitor the expression level of the receptor. The differences in swarm rates that did occur on minimal and aspartate plates of different classes could be traced to the differences in expression level (data not shown).

Because swarm assay is only a semiquantitative assay to measure chemotaxis and because several factors could affect swarm rates, we also did some in vitro biochemical studies on some of the mutants. First we did immunoblotting experiments on the membrane samples and found that the mutant receptors still associate with the membrane after high salt washes (data not shown), indicating that the mutated N-terminal tail region could still function as a leader peptide.

To determine whether the mutations caused any significant change in the tertiary and quartenary structures of the receptor, the aspartate binding affinities of the mutants were tested. Table 3listed the binding parameters of the wild type and some of the mutants. The dissociation constants (K(d)) were within a 2-fold range of that of the wild type. The mutations at the N-terminal cytoplasmic region did not alter the binding affinity for aspartate of the receptor significantly. The index for cooperatively (the Hill coefficient (n(H))) of each mutant tested (except for R4K) was within the previously published range, 0.6-0.8(20) , indicating that the binding behavior was similar to that of the wild type.



We then used methylation assays as a test of signal transduction in vitro. As shown in Fig. 3and 4 for the wild type and each of the mutants tested, aspartate increased the methylation rates in a similar manner to wild type. In the reconstituted system (Fig. 4), the addition of aspartate increased the methylation rate of the wild type by 1.8-fold. For the DeltaR4 mutant and Delta2-5 mutant, the increase was 1.9- and 1.7-fold, respectively. The reactions with no purified receptor showed minimal levels of methylation in the presence and the absence of aspartate.


Figure 3: Methylation rate ratios of the N-terminal mutants in a membrane vesicle system. Methylation assays were performed at 37 °C in the presence and the absence of aspartate. The methylation rates were the slopes of the linear fits of the time-course data points. The ratio of each receptor was the value of the methylation rate in the presence of aspartate divided by that in the absence of aspartate. wt, wild type.




Figure 4: Methylation rates of the N-terminal mutants in a reconstituted system. Partially purified receptor samples were incubated with the null membrane at room temperature for at least 45 min prior to the methylation assays, which were performed at 37 °C in the presence and the absence of aspartate. The methylation rates were the slopes of the linear fits of the time-course data points. The rates were normalized to the methylation rate of the wild type receptor in the absence of aspartate. For each receptor, the column on the left is the rate in the presence of aspartate, and the column on the right is that in the absence of aspartate.



To probe the possible motion of TM 1 within each subunit (either a piston-like motion or a rotation), we compared the rates of disulfide bond formation of two cysteine mutants in the presence and the absence of aspartate. They looked virtually identical for each mutant, as shown in Fig. 5. Based on a previous cross-linking study(24) , residues 4 and 4` are at the dimer interface, with the closest distance among the N-terminal tail residues. The inserted cysteine residue of the ICys2 mutant is located at the position for methionine residue in the wild type receptor. The side chain of this residue faces the second transmembrane segment within the same subunit.


Figure 5: Cross-linking time-courses of the ICys2 mutant. Cross-linking reactions were performed in the presence of 1 mM copper-phenanthroline at 37 °C. Aliquots were removed at various times, and the reaction was quenched to yield the reaction coordinate, the fraction of the receptor that was cross-linked (cpm of the dimeric receptor divided by the sum of cpm of the dimeric and monomeric receptor). The filled circles were the points in the presence of aspartate, and the open circles were those in the absence of aspartate. The time-courses of the R4C mutant looked similar to those of the ICys2 mutant.




DISCUSSION

The results reported herein indicate that major changes can be made in the N-terminal peptide projecting into cytoplasm with very minor effects on either transmembrane signaling or aspartate binding ability. The mutants did not interfere with insertion into the membrane or the folding of the cytoplasmic domain.

Previous studies showed that a TM 1-less receptor (first 30 amino acid residues deleted) was not functional as determined by both swarm assays and methylation assays(25) . However, we found that deletion of four residues at the N-terminal end did not affect chemotaxis significantly. Thus the TM 1 transmembrane region is important, but the peptide extending from the TM 1 region into the cytoplasm is not. This suggests that the transmembrane helices (TM 1 and TM 1`) are important in maintaining the structural integrity of the whole receptor and probably the transmembrane signaling. A distortion of these interactions would lead to abolished function of the receptor, as shown by the A19K mutant in TM 1 (11) and the 204 mutants in TM 2(26) .

It has also been found that when TM 1 and 1` were cross-linked by a Cys^4-Cys(24) , Cys^18-Cys(27) , or Cys-Cys(9) disulfide bond, the receptor could still signal as determined by methylation. This observation leads to the conclusion that TM 1 and TM 1` do not change position relative to each other during transmembrane signaling, and it is confirmed by similar reactions of a Cys^4-Cys/C-Cys double cross-linked receptor(28) .

If the interaction of the N-terminal hexapeptide with the cytoplasmic signaling domain is eliminated as a source of the indicated transmembrane conformational change, then the entire transmission of the signal that is delivered to the cytoplasmic domain must go through TM 2. Clearly that severely limits the mechanism for such transmembrane signaling. A rotation model, as suggested by Maruyama et al.(29) , seems unlikely as a sole contributor to the transmembrane signaling. Rotation of the two cytoplasmic subunits relative to each other would be excluded as a transmembrane signaling option by the results of Milligan and Koshland(10) , in which the cytoplasmic portion of one subunit could be eliminated with only a minor effect on signaling. Thus a piston model(30) , in which the cytoplasmic domain moves relative to the membrane, or a model involving relative motion of transmembrane segments TM 2 and TM 2` seems indicated. Such a model could also explain the transmembrane signaling of the epidermal growth hormone and low density lipoprotein receptors, which have one transmembrane region per receptor subunit.


FOOTNOTES

*
This work was supported by National Institutes of Health Grant DK09765 (to D. E. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed.

(^1)
The abbreviations used are: TM, transmembrane; OG, n-octyl-beta-D-glucopyranoside; LB+Amp, Luria broth with 100 µg/ml ampicillin; PMSF, phenylmethylsulfonyl fluoride.


REFERENCES

  1. Ullrich, A., and Schlessinger, J. (1990) Cell 61,203-212 [Medline] [Order article via Infotrieve]
  2. Lemmon, M. A., and Schlessinger, J. (1994) Trends Biochem. Sci. 19,459-463 [CrossRef][Medline] [Order article via Infotrieve]
  3. Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991) Science 254,821-825 [Medline] [Order article via Infotrieve]
  4. Baron, V., Kaliman, P., Gautier, N., and Van Obberghen, E. (1992) J. Biol. Chem. 267,23290-23294 [Abstract/Free Full Text]
  5. Milligan, D. L., and Koshland, D. E., Jr. (1988) J. Biol. Chem. 263,6268-6275 [Abstract/Free Full Text]
  6. Riedal, H., Dull, T. J., Honegger, A. M., Schlessinger, J., and Ullrich, A. (1989) EMBO J. 8,2943-2954 [Abstract]
  7. Moe, G. R., Bollag, G. E., and Koshland, D. E., Jr. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,5683-5687 [Abstract]
  8. Milburn, M. V., Prive, G. G., Milligan, D. L., Scott, W. G., Yeh, J., Jancarik, J., Koshland, D. E., Jr., and Kim, S.-H. (1991) Science 254,1342-1347 [Medline] [Order article via Infotrieve]
  9. Falke, J. J., and Koshland, D. E., Jr. (1987) Science 237,1596-1600 [Medline] [Order article via Infotrieve]
  10. Milligan, D. L., and Koshland, D. E. (1991) Science 254,1651-1654 [Medline] [Order article via Infotrieve]
  11. Oosawa, K., and Simon M. I. (1986) Proc. Natl. Acad. Sci. U. S. A. 83,6930-6934 [Abstract]
  12. Hunter, T., Lindberg, R. A., Middlemas, D. S., Tracy, S., and Van der Geer, P. (1992) Cold Spring Harbor Symp. Quant. Biol. 57,25-41 [Medline] [Order article via Infotrieve]
  13. Romeo, C., Kolanus, W., Amiot, M., and Seed, B. (1992) Cold Spring Harbor Symp. Quant. Biol. 57,117-125 [Medline] [Order article via Infotrieve]
  14. Van der Geer, P., Hunter, T., and Lindberg, R. A. (1994) Annu. Rev. Cell Biol. 10,251-337 [CrossRef]
  15. Wolfe, A. J., Conley, M. P., and Berg, H. C. (1988) Proc. Natl. Acad. Sci. U. S. A. 85,6711-6715 [Abstract]
  16. Vogel, H. J., and Bonner, D. M. (1956) J. Biol. Chem. 218,97-106 [Free Full Text]
  17. Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,488-492 [Abstract]
  18. Bradford, M. M. (1976) Anal. Biochem. 72,248-254 [CrossRef][Medline] [Order article via Infotrieve]
  19. Clarke, S., and Koshland, D. E., Jr. (1979) J. Biol. Chem. 254,9695-9702 [Abstract]
  20. Biemann, H.-P., and Koshland, D. E., Jr. (1994) Biochemistry 33,629-634 [Medline] [Order article via Infotrieve]
  21. Shapiro, M. J., and Koshland, D. E., Jr. (1994) J. Biol. Chem. 269,11054-11059 [Abstract/Free Full Text]
  22. Chelsky, D., Gutterson, N. I., and Koshland, D. E., Jr. (1984) Anal. Biochem. 141,143-148 [Medline] [Order article via Infotrieve]
  23. Russo, A. F., and Koshland, D. E., Jr. (1983) Science 220,1016-1020 [Medline] [Order article via Infotrieve]
  24. Stoddard, B. L., Bui, J. D., and Koshland, D. E., Jr. (1993) Biochemistry 31,11978-11983
  25. Milligan, D. L. (1991) Structure and Dynamics of the Aspartate Chemoreceptor , Ph.D. thesis, University of California, Berkeley
  26. Jeffrey, C. J., and Koshland, D. E., Jr. (1994) Biochemistry 33,3457-3463 [Medline] [Order article via Infotrieve]
  27. Lynch, B. A., and Koshland, D. E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,10402-10406 [Abstract]
  28. Scott, W. G., and Stoddard, B. L. (1994) Structure 2,877-887 [Medline] [Order article via Infotrieve]
  29. Maruyama, I., Mikawa, Y., and Maruyama, H. (1995) J. Mol. Biol. , in press
  30. Stoddard, B. L., Biemann, H.-P., and Koshland, D. E. (1992) Cold Spring Harbor Symp. Quant. Biol. 57,1-15 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.